Recent progress in the structure determination of GPCRs, a membrane protein family with high potential as pharmaceutical targets.
about
Crystallization of membrane proteins in lipidic mesophasesMass spectrometry-based proteomics of human cannabinoid receptor 2: covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation.Protein engineering methods applied to membrane protein targets.X-ray Transparent Microfluidic Chip for Mesophase-Based Crystallization of Membrane Proteins and On-Chip Structure Determination.A computationally designed water-soluble variant of a G-protein-coupled receptor: the human mu opioid receptor.Femtosecond crystallography of membrane proteins in the lipidic cubic phase.From laptop to benchtop to bedside: structure-based drug design on protein targets.Characterization of a computationally designed water-soluble human μ-opioid receptor variant using available structural informationThe Dynamic Process of Drug-GPCR Binding at Either Orthosteric or Allosteric Sites Evaluated by MetadynamicsFragment-based lead discovery on G-protein-coupled receptors.Using macromolecular-crystallography beamline and microfluidic platform for small-angle diffraction studies of lipidic matrices for membrane-protein crystallizationDifferential stability of the crystallographic interfaces of mu- and kappa-opioid receptorsLipidic cubic phase technologies for membrane protein structural studies.Mapping human protease-activated receptor 4 (PAR4) homodimer interface to transmembrane helix 4Harvesting and cryo-cooling crystals of membrane proteins grown in lipidic mesophases for structure determination by macromolecular crystallographyPharmacological modulation of chemokine receptor function.Lipid crystallization: from self-assembly to hierarchical and biological ordering.The orexin OX(1) receptor exists predominantly as a homodimer in the basal state: potential regulation of receptor organization by both agonist and antagonist ligands.Development of an Automated High Throughput LCP-FRAP Assay to Guide Membrane Protein Crystallization in Lipid Mesophases.Status of GPCR modeling and docking as reflected by community-wide GPCR Dock 2010 assessment.Structural biology: How opioid drugs bind to receptors.Molecular Dynamics Simulations of G Protein-Coupled Receptors.Molecular dynamics simulations and structure-based network analysis reveal structural and functional aspects of G-protein coupled receptor dimer interactions.Approaches for Preparation and Biophysical Characterization of Transmembrane β-Barrels
P2860
Q30155586-198FE7B5-3543-40C4-A67E-4CD63A5BC12CQ30406301-10BB16D8-6186-48A0-85C5-FB5F70C628E9Q30423115-120E1073-0C4A-44BF-86DA-E6FAD1B0BD40Q30588657-8D5AE06E-333B-4E01-A32B-E9976633A2E9Q31120649-B4821FC3-D483-494A-B2F2-D7020631D946Q33738369-A0C50753-B1B5-4C6D-A431-A24232DB2AD0Q34153589-375874A9-C712-476F-A8CC-E2110E65B983Q34243587-9A8B8A73-0252-4EC1-9D61-9927F211F6FAQ34489039-54CD93EE-E0DB-4A4E-A0A8-C6CB34E1F4EAQ34690000-38C3E9C0-E3BA-4D46-891C-B34152D4CA75Q35047991-FD871729-39C8-4ADC-9802-52526C39BDFEQ35126350-EB725308-8F92-47A4-83F3-15B07E2BC8B3Q35187977-5B2B287C-A20B-4C8D-96EC-6AD92F540407Q35879995-C150986F-A6E7-4297-8C84-E20BE3EBBD7EQ36359772-F631B85B-5648-4794-B767-074619FF3772Q37893687-047B6C64-E792-4744-84AE-E5D81FC371B9Q38035193-BC7D2893-C797-458E-AF1A-65BAE253D763Q39504323-38FEEF47-B597-4F51-8B1E-6EBE6ADEB7E3Q42746161-60057FAF-613A-49F7-9A4F-3DDF77C92484Q42863821-17945E2D-D5C5-4146-992A-1261C9FFDFD4Q43235004-E759B88C-290F-4660-8AEC-DD3A5253D8E2Q51603766-2BD00F4C-0AE5-4835-9D51-006DB0ED8FCFQ51678306-575B22F5-8EDB-4BB3-8473-09FAF9BBEEB5Q57810611-641194D0-5A30-4015-A43B-B914F09B2CF9
P2860
Recent progress in the structure determination of GPCRs, a membrane protein family with high potential as pharmaceutical targets.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Recent progress in the structu ...... ial as pharmaceutical targets.
@ast
Recent progress in the structu ...... ial as pharmaceutical targets.
@en
Recent progress in the structu ...... ial as pharmaceutical targets.
@nl
type
label
Recent progress in the structu ...... ial as pharmaceutical targets.
@ast
Recent progress in the structu ...... ial as pharmaceutical targets.
@en
Recent progress in the structu ...... ial as pharmaceutical targets.
@nl
prefLabel
Recent progress in the structu ...... ial as pharmaceutical targets.
@ast
Recent progress in the structu ...... ial as pharmaceutical targets.
@en
Recent progress in the structu ...... ial as pharmaceutical targets.
@nl
P2093
P2860
P921
P1476
Recent progress in the structu ...... ial as pharmaceutical targets.
@en
P2093
Enrique Abola
Raymond C Stevens
Vadim Cherezov
P2860
P304
P356
10.1007/978-1-60761-762-4_8
P407
P577
2010-01-01T00:00:00Z